ðŠ 2020 ðŠ ãã¬ãã¥ãŒ
2020幎ã¯ç§ã®æåã®ãã«ã€ã€ãŒã§ãããã³ãããŠã€ã«ã¹ãéžæããœãããã³ã¯ã«ãã人工æè¡ããã«ã貿ææŠäºãå°éããã³åºæ¿æ³æ¡ã®è©±ãåãã«ããã倧å€ãªå¹Žã§ãããä»ã®äººã
ã¯ããã®åžå Žã§ã®ïŒå¹Žã¯çµéšçã«ïŒå¹Žåã«ã«ãŠã³ããããã¹ãã§ãããšèšã£ãŠããŸããããããã«ã¯ãŸã£ããåæã§ããŸãïŒãããã£ãŠã波乱ãä¹ãè¶ããå£åº§ããæã¡ã®çããã«ããã§ãšãããããŸãã
2020幎ã®ç§ã®æåããæŠç¥ã®ããã€ã:
1. FDAã®äºåPDUFAã©ã³(ãããã²ã€ããŒ#1 AQSTã#4 ADMP)ãç§ã¯ä»¥äžã®ã«ã¬ã³ããŒã䜿çšããŠãPDUFAæ¥ã®2-3ã¶æåã«è²·ããPDUFAæ¥ã®çŽ3é±éåã«å£²ããŸãhttps://www.biopharmcatalyst.com/calendars/pdufa-calendarã
2. ããæ¥çžŸã®å åãã©ã³ãç¡æã®ãWeekly Anticipated Releases for the Weekãã®ã¡ãŒã«ã«ãµã€ã³ã¢ããããŠããŸãã https://www.earningswhispers.com.
1. FDAã®äºåPDUFAã©ã³(ãããã²ã€ããŒ#1 AQSTã#4 ADMP)ãç§ã¯ä»¥äžã®ã«ã¬ã³ããŒã䜿çšããŠãPDUFAæ¥ã®2-3ã¶æåã«è²·ããPDUFAæ¥ã®çŽ3é±éåã«å£²ããŸãhttps://www.biopharmcatalyst.com/calendars/pdufa-calendarã
2. ããæ¥çžŸã®å åãã©ã³ãç¡æã®ãWeekly Anticipated Releases for the Weekãã®ã¡ãŒã«ã«ãµã€ã³ã¢ããããŠããŸãã https://www.earningswhispers.com.
åææ¥ã«ã¡ãŒã«ãå±ãã®ã§ã70ïŒ
以äžã®åçã®æåŸ
å€ã®é«ãéæã®ãªã¹ããäœæããŸãã
ç¿é±ã®æææ¥ã«æ ªã賌å
¥ããåçãå
¬è¡šãããåã«å£²åŽããŸããçºè¡šã®åã«ã¯ä¿æããŸããã
3.åžæã®æ ªåŒã®åæ¹åå²ã¯éåžžã«åŒ·åãªã«ã¿ãªã¹ãã§ããããšãããããŸããã(ãããã²ã€ããŒ#2 TSLAã#3 AAPL)ãéåå²ãšæ··åããªãã§ãã ãããéåå²ã¯ãã°ãã°äŸ¡æ Œã®ãããªãäžèœãåŒãèµ·ãããã®ã§ã(以äžãåç §)ã
4. ã¢ããªã¹ãã®æ Œä»ãhttps://www.marketbeat.com/ratings/upgrades/ãšå éšååŒhttps://www.marketbeat.com/insider-trades/ïŒæ匷ïŒïŒ1 CFOãïŒ2ä»ã®Cã¬ãã«ïŒCEOãCOOïŒãïŒ3åç· åœ¹äŒãVPïŒ
5. ã¢ã¡ã³ã¿ã ãã¬ãŒã-æ¥ãªå©çãçã£ããã¬ã€ã¯ã¢ãŠãã®è³Œå ¥ãé«ãªã¹ã¯ãé«ãªã¿ãŒã³ã®æŠç¥ã
ããã¯ç§ã«ãšã£ãŠæ°ãããã®ã§ãããç§ã¯ïŒhttps://www.transparenttradersblackbox.com/?afmc=54ïŒããåŠã³ãŸããïŒæåã®1ãæã¯$1ã§ã - 2ãæç®ãå§ãŸãåã«ãã£ã³ã»ã«ãå¿ããªãã§ãã ããïŒåœŒãã¯ãã¬ã€ã¯ã¢ãŠãäŸ¡æ Œãã¹ããããã¹ãäŸ¡æ Œã¿ãŒã²ãããæäŸãããåæ»ããŠæ ªäŸ¡ãäžèœããŠãããšå€æããå Žåãã¹ããããã¹ã移åããããªããåºãããã«ã説æããŠããŸããç²ç®çã«åŸãã®ã§ã¯ãªãããªã圌ããç¹å®ã®äŸ¡æ Œãã€ã³ããäžããŠããã®ãåæããŸãããã¢ã¡ã³ã¿ã ãã¬ãŒãã£ã³ã°ã¯å šãæ°ããäžçã§ããç§ã¯æ¥å¹Žããã®æŠç¥ã«é¢ããã¹ãã«ãéçºãç¶ããŸãã6. ãã¯ãã«ã«åæã«åºã¥ãååŒïŒãµããŒãã§è²·ããã¬ãžã¹ã¿ã³ã¹ã§å£²ããŸãã¯å£²ãã§ã¬ãžã¹ã¿ã³ã¹ãäžåãããµããŒãã§ã«ããŒããŠãå€§å¹ ãªäžæãäžèœåŸã®å転ååŒããã¯ãã«ã«åæãæ°ããå Žåã¯ããã®ãããªããå§ããããšã匷ããå§ãããŸãïŒ
3.åžæã®æ ªåŒã®åæ¹åå²ã¯éåžžã«åŒ·åãªã«ã¿ãªã¹ãã§ããããšãããããŸããã(ãããã²ã€ããŒ#2 TSLAã#3 AAPL)ãéåå²ãšæ··åããªãã§ãã ãããéåå²ã¯ãã°ãã°äŸ¡æ Œã®ãããªãäžèœãåŒãèµ·ãããã®ã§ã(以äžãåç §)ã
4. ã¢ããªã¹ãã®æ Œä»ãhttps://www.marketbeat.com/ratings/upgrades/ãšå éšååŒhttps://www.marketbeat.com/insider-trades/ïŒæ匷ïŒïŒ1 CFOãïŒ2ä»ã®Cã¬ãã«ïŒCEOãCOOïŒãïŒ3åç· åœ¹äŒãVPïŒ
5. ã¢ã¡ã³ã¿ã ãã¬ãŒã-æ¥ãªå©çãçã£ããã¬ã€ã¯ã¢ãŠãã®è³Œå ¥ãé«ãªã¹ã¯ãé«ãªã¿ãŒã³ã®æŠç¥ã
ããã¯ç§ã«ãšã£ãŠæ°ãããã®ã§ãããç§ã¯ïŒhttps://www.transparenttradersblackbox.com/?afmc=54ïŒããåŠã³ãŸããïŒæåã®1ãæã¯$1ã§ã - 2ãæç®ãå§ãŸãåã«ãã£ã³ã»ã«ãå¿ããªãã§ãã ããïŒåœŒãã¯ãã¬ã€ã¯ã¢ãŠãäŸ¡æ Œãã¹ããããã¹ãäŸ¡æ Œã¿ãŒã²ãããæäŸãããåæ»ããŠæ ªäŸ¡ãäžèœããŠãããšå€æããå Žåãã¹ããããã¹ã移åããããªããåºãããã«ã説æããŠããŸããç²ç®çã«åŸãã®ã§ã¯ãªãããªã圌ããç¹å®ã®äŸ¡æ Œãã€ã³ããäžããŠããã®ãåæããŸãããã¢ã¡ã³ã¿ã ãã¬ãŒãã£ã³ã°ã¯å šãæ°ããäžçã§ããç§ã¯æ¥å¹Žããã®æŠç¥ã«é¢ããã¹ãã«ãéçºãç¶ããŸãã6. ãã¯ãã«ã«åæã«åºã¥ãååŒïŒãµããŒãã§è²·ããã¬ãžã¹ã¿ã³ã¹ã§å£²ããŸãã¯å£²ãã§ã¬ãžã¹ã¿ã³ã¹ãäžåãããµããŒãã§ã«ããŒããŠãå€§å¹ ãªäžæãäžèœåŸã®å転ååŒããã¯ãã«ã«åæãæ°ããå Žåã¯ããã®ãããªããå§ããããšã匷ããå§ãããŸãïŒ
7. æªããã¥ãŒã¹ã«ãã空売ãïŒ- offerings and shelf registrations (https://moo.moomoo.com/nnq/hdetail?id=105410810281989&lang_code=2)- bad earnings or poor guidance released- CRL from FDA or failed medical trials- insiders selling: 1) a large amount (in $ or %) within short period of time; 2) selling into weakness (at decreasing prices)- reverse split announcement and first day after the split (https://eresearch.fidelity.com/eresearch/conferenceCalls.jhtml?tab=splits)
æ°å¹Žã®æ±è² ïŒ1.ææ ç/埩è®ååŒãããªãã§ãã ãããå·éã«ããŠããµã€ãºããŠã³ããŠãèªä¿¡ãåãæ»ããäœããªãã£ãããã«ãã¬ãŒãããŠãã ããã2.倱æããå Žåãè² ãããã®ã«å ããªãã§ãã ãããæ倱ãåãã次ã«é²ãã§ãã ããã3.èšç»ã«åŸããæåŸã®ç¬éã«å€æŽããªãã§ãã ããã4.ã»ããã¢ãããæ£ããå ŽåãååŒããæ¥ãã§åºãŠããŠã¯ãããŸãããæéããããŠè§£æ±ºããŠãã ããã5.ç°ãªãæŠç¥ãã»ã¯ã¿ãŒã®å€æ§åã«åãçµãã§ãã ããã1ã€ã®ååŒã«20ïŒ ä»¥äžãæå ¥ããªãã§ãã ããã
æ°å¹Žã®æ±è² ïŒ1.ææ ç/埩è®ååŒãããªãã§ãã ãããå·éã«ããŠããµã€ãºããŠã³ããŠãèªä¿¡ãåãæ»ããäœããªãã£ãããã«ãã¬ãŒãããŠãã ããã2.倱æããå Žåãè² ãããã®ã«å ããªãã§ãã ãããæ倱ãåãã次ã«é²ãã§ãã ããã3.èšç»ã«åŸããæåŸã®ç¬éã«å€æŽããªãã§ãã ããã4.ã»ããã¢ãããæ£ããå ŽåãååŒããæ¥ãã§åºãŠããŠã¯ãããŸãããæéããããŠè§£æ±ºããŠãã ããã5.ç°ãªãæŠç¥ãã»ã¯ã¿ãŒã®å€æ§åã«åãçµãã§ãã ããã1ã€ã®ååŒã«20ïŒ ä»¥äžãæå ¥ããªãã§ãã ããã
ãã¯ãã«ã«åæã«åºã¥ãååŒïŒãµããŒãã§è²·ããã¬ãžã¹ã¿ã³ã¹ã§å£²ããŸãã¯å£²ãã§ã¬ãžã¹ã¿ã³ã¹ãäžåãããµããŒãã§ã«ããŒããŠãå€§å¹ ãªäžæãäžèœåŸã®å転ååŒããã¯ãã«ã«åæãæ°ããå Žåã¯ããã®ãããªããå§ããããšã匷ããå§ãããŸãïŒ
7. æªããã¥ãŒã¹ã«ããæ°èŠå£²ãïŒ- offerings and shelf registrations (https://moo.moomoo.com/nnq/hdetail?id=105410810281989&lang_code=2)- bad earnings or poor guidance released- CRL from FDA or failed medical trials- insiders selling: 1) a large amount (in $ or %) within short period of time; 2) selling into weakness (at decreasing prices)- reverse split announcement and first day after the split (https://eresearch.fidelity.com/eresearch/conferenceCalls.jhtml?tab=splits)
- å ¬éå¢è³ããã³å£²äžå¯èœãªæ䟡蚌åžç»é²æžã®çºè¡https://moo.moomoo.com/nnq/hdetail?id=105410810281989&lang_code=2
- æªãæ¥çžŸãŸãã¯äžæ¯ãªèŠéãã®çºè¡š
å»çé¢é£ã®CRLãŸãã¯å€±æããèšåºè©Šéš
- ã€ã³ãµã€ããŒå£²ãïŒ1ïŒçæéã§ã®å€§éã®å£²åŽïŒ$ãŸãã¯ïŒ ïŒïŒ2ïŒåŒ±å«ã¿çžå Žã§ã®å£²åŽïŒäžèœäŸ¡æ Œã§å£²åŽããããšïŒ
ãªããŒã¹ããªããã®çºè¡šãšåå²åŸã®æåã®æ¥ïŒhttps://eresearch.fidelity.com/eresearch/conferenceCalls.jhtml?tab=splitsïŒãªããŒã¹ããªããã®çºè¡šãšåå²åŸã®æåã®æ¥ïŒhttps://eresearch.fidelity.com/eresearch/conferenceCalls.jhtml?tab=splitsïŒ
æ°å¹Žã®æ±è² ïŒ1.ææ ç/埩è®ååŒãããªãã§ãã ãããå·éã«ããŠããµã€ãºããŠã³ããŠãèªä¿¡ãåãæ»ããäœããªãã£ãããã«ãã¬ãŒãããŠãã ããã2.倱æããå Žåãè² ãããã®ã«å ããªãã§ãã ãããæ倱ãåãã次ã«é²ãã§ãã ããã3.èšç»ã«åŸããæåŸã®ç¬éã«å€æŽããªãã§ãã ããã4.ã»ããã¢ãããæ£ããå ŽåãååŒããæ¥ãã§åºãŠããŠã¯ãããŸãããæéããããŠè§£æ±ºããŠãã ããã5.ç°ãªãæŠç¥ãã»ã¯ã¿ãŒã®å€æ§åã«åãçµãã§ãã ããã1ã€ã®ååŒã«20ïŒ ä»¥äžãæå ¥ããªãã§ãã ããã
æ°å¹Žã®æ±è² ïŒ1.ææ ç/埩è®ååŒãããªãã§ãã ãããå·éã«ããŠããµã€ãºããŠã³ããŠãèªä¿¡ãåãæ»ããäœããªãã£ãããã«ãã¬ãŒãããŠãã ããã2.倱æããå Žåãè² ãããã®ã«å ããªãã§ãã ãããæ倱ãåãã次ã«é²ãã§ãã ããã3.èšç»ã«åŸããæåŸã®ç¬éã«å€æŽããªãã§ãã ããã4.ã»ããã¢ãããæ£ããå ŽåãååŒããæ¥ãã§åºãŠããŠã¯ãããŸãããæéããããŠè§£æ±ºããŠãã ããã5.ç°ãªãæŠç¥ãã»ã¯ã¿ãŒã®å€æ§åã«åãçµãã§ãã ããã1ã€ã®ååŒã«20ïŒ ä»¥äžãæå ¥ããªãã§ãã ããã
æ°å¹Žã®æ±è² ïŒ1.ææ ç/埩è®ååŒãããªãã§ãã ãããå·éã«ããŠããµã€ãºããŠã³ããŠãèªä¿¡ãåãæ»ããäœããªãã£ãããã«ãã¬ãŒãããŠãã ããã2.倱æããå Žåãè² ãããã®ã«å ããªãã§ãã ãããæ倱ãåãã次ã«é²ãã§ãã ããã3.èšç»ã«åŸããæåŸã®ç¬éã«å€æŽããªãã§ãã ããã4.ã»ããã¢ãããæ£ããå ŽåãååŒããæ¥ãã§åºãŠããŠã¯ãããŸãããæéããããŠè§£æ±ºããŠãã ããã5.ç°ãªãæŠç¥ãã»ã¯ã¿ãŒã®å€æ§åã«åãçµãã§ãã ããã1ã€ã®ååŒã«20ïŒ ä»¥äžãæå ¥ããªãã§ãã ããã
æ°å¹Žã®æ±è² ïŒ1.ææ ç/埩è®ååŒãããªãã§ãã ãããå·éã«ããŠããµã€ãºããŠã³ããŠãèªä¿¡ãåãæ»ããäœããªãã£ãããã«ãã¬ãŒãããŠãã ããã2.倱æããå Žåãè² ãããã®ã«å ããªãã§ãã ãããæ倱ãåãã次ã«é²ãã§ãã ããã3.èšç»ã«åŸããæåŸã®ç¬éã«å€æŽããªãã§ãã ããã4.ã»ããã¢ãããæ£ããå ŽåãååŒããæ¥ãã§åºãŠããŠã¯ãããŸãããæéããããŠè§£æ±ºããŠãã ããã5.ç°ãªãæŠç¥ãã»ã¯ã¿ãŒã®å€æ§åã«åãçµãã§ãã ããã1ã€ã®ååŒã«20ïŒ ä»¥äžãæå ¥ããªãã§ãã ããã
æ°å¹Žã®æ±è² ïŒ1.ææ ç/埩è®ååŒãããªãã§ãã ãããå·éã«ããŠããµã€ãºããŠã³ããŠãèªä¿¡ãåãæ»ããäœããªãã£ãããã«ãã¬ãŒãããŠãã ããã2.倱æããå Žåãè² ãããã®ã«å ããªãã§ãã ãããæ倱ãåãã次ã«é²ãã§ãã ããã3.èšç»ã«åŸããæåŸã®ç¬éã«å€æŽããªãã§ãã ããã4.ã»ããã¢ãããæ£ããå ŽåãååŒããæ¥ãã§åºãŠããŠã¯ãããŸãããæéããããŠè§£æ±ºããŠãã ããã5.ç°ãªãæŠç¥ãã»ã¯ã¿ãŒã®å€æ§åã«åãçµãã§ãã ããã1ã€ã®ååŒã«20ïŒ ä»¥äžãæå ¥ããªãã§ãã ããã
æ°å¹Žã®æ±è² ïŒ1.ææ ç/埩è®ååŒãããªãã§ãã ãããå·éã«ããŠããµã€ãºããŠã³ããŠãèªä¿¡ãåãæ»ããäœããªãã£ãããã«ãã¬ãŒãããŠãã ããã2.倱æããå Žåãè² ãããã®ã«å ããªãã§ãã ãããæ倱ãåãã次ã«é²ãã§ãã ããã3.èšç»ã«åŸããæåŸã®ç¬éã«å€æŽããªãã§ãã ããã4.ã»ããã¢ãããæ£ããå ŽåãååŒããæ¥ãã§åºãŠããŠã¯ãããŸãããæéããããŠè§£æ±ºããŠãã ããã5.ç°ãªãæŠç¥ãã»ã¯ã¿ãŒã®å€æ§åã«åãçµãã§ãã ããã1ã€ã®ååŒã«20ïŒ ä»¥äžãæå ¥ããªãã§ãã ããã
çãããæåãã2021幎ããè¿ããã ããïŒ
å¯äžã®ãã¡ã³ã«æ§ããããŸãã @PREMOSULTRA
å
責äºé
ïŒãã®ã³ãã¥ããã£ã¯ãMoomoo Technologies Inc.ãæè²ç®çã§ã®ã¿æäŸãããã®ã§ãã
ããã«è©³ããæ
å ±
ã³ã¡ã³ã
ãµã€ã³ã€ã³ã³ã¡ã³ãããã
PREMOSULTRAA : ãããŒãçŽ æŽããããŸãšãã§ããããªãã®ãã¡ã³ã¯ç§ã ãã§ã¯ãªããšç¢ºä¿¡ããŠããŸã
Amabel : ããããšããããªãã奜ããªããŒã«ã¯ãªãŒãºããã«ã§ãïŒMOOOã䌌ããããªããŒã«ãè¿œå ããŠååŒããŒã«ãäœãããšãé¡ã£ãŠããŸãã
finance_analyst ã¹ã¬äž» PREMOSULTRAA : ããŠã2ã€ç®ãæã«å ¥ããã°ã100ïŒ æé·ããŸã
finance_analyst ã¹ã¬äž» Amabel : ããããšãããããååã®ãã¹ãã³ã³ããã£ã·ã§ã³ã®ç®çã§ãããä»ã®ãšãããå°ãªããšããã¥ãŒã¹ãæç³»åã«èŒããŠãããããšãæåŸ ããŠããŸã
OldNormanBates finance_analyst ã¹ã¬äž» : åææçè¡šã¯ã©ãã«ãããŸãããä»æã®ç§ã¯äžçãããèŠã€ããããšãã§ããŸããã§ãããããããã¬ããŒã±ããã®å¶æ¥æéã«ãããããã®ã§ããç¬ãæçš¿ãæ°ã«å ¥ããŸãã
finance_analyst ã¹ã¬äž» OldNormanBates : Tradeã¿ããéããããã°ã©ããã¯ãªãã¯ããŠãã ãããæ°ãããŠã£ã³ããŠã§ãP/Låæããã¯ãªãã¯ããŸã
OldNormanBates finance_analyst ã¹ã¬äž» : æ å ±ããããšãããããŸã
Moomoo Event : ããã«ã¡ã¯ïŒå¿ã®ããã£ãã¬ãã¥ãŒãã·ã§ã¢ããŠãããŠããããšãã䟿å®äžãåç»ãªã³ã¯ãããã¹ãã«çŽæ¥è²Œãä»ãã代ããã«ã次åã¯ããããªãªã³ã¯ãã«ãªã³ã¯ãæ·»ä»ã§ããŸãïŒäžã®åçãåç §ïŒããããŠããããªã«ããŒã¯èªåçã«åŒãåºãããŸãã
finance_analyst ã¹ã¬äž» Moomoo Event : ãããŒïŒãã®æ©èœãçµ±åããŠçŽ¹ä»ããŠãããŠããããšããé«ãè©äŸ¡ããŠããŸããæŽæ°ããŸãã
Moomoo Event finance_analyst ã¹ã¬äž» : ãã¡ããïŒãååããã ãããããšãããããŸãã
ãã£ãšã³ã¡ã³ããèŠã...